Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Steroid receptor agonist

DRUG CLASS:

Steroid receptor agonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

prednisone (24)

dexamethasone injection (0)

prednisone (24)

dexamethasone injection (0)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	prednisone Sensitive: A2 - Guideline prednisone Sensitive : A2	prednisone Sensitive: A2 - Guideline prednisone Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	prednisone Sensitive: A2 - Guideline prednisone Sensitive : A2	prednisone Sensitive: A2 - Guideline prednisone Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	vincristine + prednisone Sensitive: A2 - Guideline vincristine + prednisone Sensitive : A2	vincristine + prednisone Sensitive: A2 - Guideline vincristine + prednisone Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	vincristine + prednisone + daunorubicin + pegaspargase Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase Sensitive : A2	vincristine + prednisone + daunorubicin + pegaspargase Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase Sensitive : A2
No biomarker	T Acute Lymphoblastic Leukemia	No biomarker	T Acute Lymphoblastic Leukemia	vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive : A2	vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	vincristine + prednisone + daunorubicin + pegaspargase Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase Sensitive : A2	vincristine + prednisone + daunorubicin + pegaspargase Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase Sensitive : A2
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
FBXW7 mutation	T Acute Lymphoblastic Leukemia	FBXW7 mutation	T Acute Lymphoblastic Leukemia	prednisone Resistant: C3 – Early Trials prednisone Resistant : C3	prednisone Resistant: C3 – Early Trials prednisone Resistant : C3